Systemic therapy for hepatocellular carcinoma: The issue of treatment stage migration and registration of progression using the BCLC-refined RECIST

Seminars in Liver Disease

Volumn 34, Issue 4, 2014, Pages 444-455

  Reig, Maria ^a,b   Darnell, Anna ^a   Forner, Alejandro ^a,b   Rimola, Jordi ^a,b   Ayuso, Carmen ^a,b   Bruix, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

BCLC RECIST; BCLC staging; hepatocellular carcinoma; RECIST; survival; treatment; trial design

Indexed keywords

BRIVANIB; EVEROLIMUS; LINIFANIB; RAMUCIRUMAB; SUNITINIB; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84928531309     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1394143     Document Type: Article

References (81)

1. Forner A., Llovet J. M., Bruix J. Hepatocellular carcinoma. Lancet: 2012; 379 9822 1245 1255
2. Bruix J., Sherman M.; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology: 2011; 53 3 1020 1022
3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol: 2012; 56 4 908 943
4. Verslype C., Rosmorduc O., Rougier P.; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: 2012; 23 07 vii41 vii48
5. Sorensen J. B., Klee M., Palshof T., Hansen H. H. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer: 1993; 67 4 773 775
6. Bruix J., Reig M., Rimola J., et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology: 2011; 54 6 2238 2244
7. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg: 1973; 60 8 646 649
8. Tsochatzis E. A., Bosch J., Burroughs A. K. Liver cirrhosis. Lancet: 2014; 383 9930 1749 1761
9. Malinchoc M., Kamath P. S., Gordon F. D., Peine C. J., Rank J., ter Borg P. C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology: 2000; 31 4 864 871
10. Fede G., D'Amico G., Arvaniti V., et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol: 2012; 56 4 810 818
11. Wong F., O'Leary J. G., Reddy K. R., et al. North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology: 2013; 145 6 1280 1288, e1
12. Martin P., DiMartini A., Feng S., Brown R. Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology: 2014; 59 3 1144 1165
13. Barreto R., Fagundes C., Guevara M., et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology: 2014; 59 4 1505 1513
14. Raoul J. L., Sangro B., Forner A., et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev: 2011; 37 3 212 220
15. Reig M., Rimola J., Torres F., et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology: 2013; 58 6 2023 2031
16. Sieghart W., Hucke F., Pinter M., et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology: 2013; 57 6 2261 2273
17. Bruix J., Sherman M.; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology: 2005; 42 5 1208 1236
18. Castells A., Bruix J., Brú C., et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology: 1995; 109 3 917 922
19. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology: 2004; 40 6 1361 1369
20. Llovet J. M., Sala M., Castells L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology: 2000; 31 1 54 58
21. Beaugrand M., Sala M., Degos F. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an international randomized double-blind placebo-controlled study in 747 patients. J Hepatol: 2005; 42 17A
22. Llovet J. M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 4 378 390
23. Cheng A. L., Kang Y. K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol: 2009; 10 1 25 34
24. Abou-Alfa G. K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2006; 24 26 4293 4300
25. Therasse P., Arbuck S. G., Eisenhauer E. A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst: 2000; 92 3 205 216
26. Cabibbo G., Enea M., Attanasio M., Bruix J., Craxì A., Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology: 2010; 51 4 1274 1283
27. Llovet J. M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology: 1999; 29 1 62 67
28. Llovet J. M., Di Bisceglie A. M., Bruix J., et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst: 2008; 100 10 698 711
29. Raoul J. L., Bruix J., Greten T. F., et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol: 2012; 56 5 1080 1088
30. Bruix J., Raoul J. L., Sherman M., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol: 2012; 57 4 821 829
31. Llovet J. M., Peña C. E., Lathia C. D., Shan M., Meinhardt G., Bruix J.; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res: 2012; 18 8 2290 2300
32. Reig M., Torres F., Rodriguez-Lope C., et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol: 2014; 61 2 318 324
33. Finn R. S. Drug therapy: sorafenib. Hepatology: 2010; 51 5 1843 1849
34. Iavarone M., Cabibbo G., Piscaglia F., et al. SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology: 2011; 54 6 2055 2063
35. Abou-Alfa G. K. Sorafenib use in hepatocellular carcinoma: more questions than answers. Hepatology: 2014; 60 1 15 18
36. Zhu A. X., Duda D. G., Sahani D. V., Jain R. K. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol: 2011; 8 5 292 301
37. Oxnard G. R., Morris M. J., Hodi F. S., et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst: 2012; 104 20 1534 1541
38. Wilhelm S. M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res: 2004; 64 19 7099 7109
39. Cheng A. L., Kang Y. K., Lin D. Y., et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol: 2013; 31 32 4067 4075
40. Johnson P. J., Qin S., Park J. W., et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol: 2013; 31 28 3517 3524
41. Cainap C., Qin S., Huang W-T., et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol: 2013; 31 04 249
42. Zhu A., Rosmorduc O., Evans J., et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol: 2012; 23 LBA2
43. Llovet J. M., Decaens T., Raoul J. L., et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol: 2013; 31 28 3509 3516
44. Zhu A. X., Kudo M., Assenat E., et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA: 2014; 312 1 57 67
45. Zhu et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: Results from the randomized phase III REACH study. ESMO 2014. LBA16. Ann Oncol: 2014; 25 04
46. Santoro A., Rimassa L., Borbath I., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol: 2013; 14 1 55 63
47. Bedard P. L., Hansen A. R., Ratain M. J., Siu L. L. Tumour heterogeneity in the clinic. Nature: 2013; 501 7467 355 364
48. Bruix J., Gores G. J., Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut: 2014; 63 5 844 855
49. Krebs M. G., Metcalf R. L., Carter L., Brady G., Blackhall F. H., Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol: 2014; 11 3 129 144
50. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol: 2013; 10 8 472 484
51. Moertel C. G., Hanley J. A. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer: 1976; 38 1 388 394
52. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland World Health Organization: 1979
53. Eisenhauer E. A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer: 2009; 45 2 228 247
54. Bruix J., Sherman M., Llovet J. M., et al. EASL Panel of Experts on HCC; European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol: 2001; 35 3 421 430
55. Riaz A., Miller F. H., Kulik L. M., et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA: 2010; 303 11 1062 1069
56. Lencioni R., Llovet J. M., Han G., et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol: 2012; 30 04 abstract LBA154
57. Kudo M., Imanaka K., Chida N., et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer: 2011; 47 14 2117 2127
58. Choi H., Charnsangavej C., Faria S. C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol: 2007; 25 13 1753 1759
59. Lencioni R., Llovet J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis: 2010; 30 1 52 60
60. Kudo M., Kubo S., Takayasu K., et al. Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res: 2010; 40 7 686 692
61. Wolchok J. D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res: 2009; 15 23 7412 7420
62. Berzigotti A., García-Criado A., Darnell A., García-Pagán J. C. Imaging in clinical decision-making for portal vein thrombosis. Nat Rev Gastroenterol Hepatol: 2014; 11 5 308 316
63. Vilana R., Bru C., Bruix J., Castells A., Sole M., Rodes J. Fine-needle aspiration biopsy of portal vein thrombus: value in detecting malignant thrombosis. AJR Am J Roentgenol: 1993; 160 6 1285 1287
64. Heo J., Reid T., Ruo L., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med: 2013; 19 3 329 336
65. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol: 2006; 6 10 715 727
66. Rosenberg S. A. Cell transfer immunotherapy for metastatic solid cancer\-what clinicians need to know. Nat Rev Clin Oncol: 2011; 8 10 577 585
67. Yeo W., Chung H. C., Chan S. L., et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol: 2012; 30 27 3361 3367
68. Straussman R., Morikawa T., Shee K., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature: 2012; 487 7408 500 504
69. Qian B. Z., Pollard J. W. Macrophage diversity enhances tumor progression and metastasis. Cell: 2010; 141 1 39 51
70. Wilson T. R., Fridlyand J., Yan Y., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature: 2012; 487 7408 505 509
71. Thomas M. B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer: 2007; 110 5 1059 1067
72. Philip P. A., Mahoney M. R., Allmer C., et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol: 2005; 23 27 6657 6663
73. Toh H. C., Chen P. J., Carr B. I., et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer: 2013; 119 2 380 387
74. Barone C., Basso M., Biolato M., et al. A phase II study of sunitinib in advanced hepatocellular carcinoma. Dig Liver Dis: 2013; 45 8 692 698
75. Koeberle D., Montemurro M., Samaras P., et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist: 2010; 15 3 285 292
76. Zhu A. X., Sahani D. V., Duda D. G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol: 2009; 27 18 3027 3035
77. Faivre S., Raymond E., Boucher E., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol: 2009; 10 8 794 800
78. Park J. W., Finn R. S., Kim J. S., et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res: 2011; 17 7 1973 1983
79. Qin S. K., Cao M. R., Qian J., et al. Clinical study of FOLFOX regimen for the patients with advanced hepatocellular carcinoma [in Chinese]. Chin Clin Oncol: 2005; 10 58 60
80. Qin S., Bai Y., Lim H. Y., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol: 2013; 31 28 3501 3508
81. Finn R. S., Kang Y. K., Mulcahy M., et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res: 2012; 18 7 2090 2098